We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

29 hedge funds and large institutions have $16.9M invested in Protara Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $14.6M → $16.9M (+$2.25M)

0.05% more ownership

Funds ownership: 48.61% → 48.66% (+0.05%)

6% less funds holding

Funds holding: 31 → 29 (-2)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

50% less call options, than puts

Call options by funds: $1K | Put options by funds: $2K

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
29
Holders Change
-2
Holders Change %
-6.45%
% of All Funds
0.46%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
1
Increased
5
Reduced
6
Closed
3
Calls
$1K
Puts
$2K
Net Calls
-$1K
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$193K
2
Citadel Advisors
Citadel Advisors
Florida
+$104K
3
LPL Financial
LPL Financial
California
+$33.1K
4
BlackRock
BlackRock
New York
+$2.42K
5
Northern Trust
Northern Trust
Illinois
+$1.88K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$123K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$51.6K
3
Two Sigma Investments
Two Sigma Investments
New York
-$34.4K
4
Renaissance Technologies
Renaissance Technologies
New York
-$26.7K
5
Millennium Management
Millennium Management
New York
-$10.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$8.08M – – –
O
2
OrbiMed
New York
$2.48M -$123K -37,083 -4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.34M – – –
PA
4
Perceptive Advisors
New York
$908K – – –
BC
5
Boxer Capital
California
$655K – – –
BBA
6
Baker Bros. Advisors
New York
$625K – – –
IC
7
Ikarian Capital
Texas
$585K – – –
PFMU
8
Privium Fund Management (UK)
United Kingdom
$401K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$259K – – –
BCM
10
Bridgeway Capital Management
Texas
$198K – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$184K -$26.7K -8,094 -12%
Morgan Stanley
12
Morgan Stanley
New York
$183K +$193K +58,339 +233,356%
Citadel Advisors
13
Citadel Advisors
Florida
$143K +$104K +31,339 +211%
BlackRock
14
BlackRock
New York
$116K +$2.42K +732 +2%
Two Sigma Investments
15
Two Sigma Investments
New York
$112K -$34.4K -10,402 -23%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$99K -$51.6K -15,600 -33%
State Street
17
State Street
Massachusetts
$95.8K – – –
Millennium Management
18
Millennium Management
New York
$82K -$10.9K -3,305 -11%
Northern Trust
19
Northern Trust
Illinois
$64.4K +$1.88K +568 +3%
BFM
20
Boothbay Fund Management
New York
$59K – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$56K – – –
Assenagon Asset Management
22
Assenagon Asset Management
Luxembourg
$54.3K – – –
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$52.2K – – –
LPL Financial
24
LPL Financial
California
$31.4K +$33.1K +10,025 New
Acadian Asset Management
25
Acadian Asset Management
Massachusetts
$19K – – –
1
2

TARA Hedge Fund Activity: Q1 2023 in Review

29 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2023, worth a combined $16.9M — up 15% from $14.6M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of TARA and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 5 added.

The largest buyer was Morgan Stanley, adding an estimated $193K. The largest seller was OrbiMed, cutting an estimated $123K.

  • 29 institutional investors held Protara Therapeutics (TARA) as of Q1 2023, down from 31 in Q4 2022.
  • Funds reported $16.9M of Protara Therapeutics stock for Q1 2023, up 15% quarter-over-quarter.
  • 1 fund opened new Protara Therapeutics positions in Q1 2023 and 3 closed out, a net change of -2 holders.
  • The largest Protara Therapeutics buyer in Q1 2023 was Morgan Stanley, an estimated $193K added.
  • The largest Protara Therapeutics seller in Q1 2023 was OrbiMed, an estimated $123K sold.

Based on aggregated 13F filings for Q1 2023.